Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

This research study is being done to find out if a drug called cemiplimab is safe in adult patients who have non-small cell lung cancer (NSCLC) that can be surgically removed (resectable Stage II, IIIA, or select IIIB NSCLC). The purpose of this study is also to look at how well the study drug works and whether certain patients can skip chemotherapy before their surgery. The goal is to see if they can safely avoid the harsh side effects of chemo and still have a successful outcome. The investigators are doing this study because the investigators want to find out if this treatment approach is

Trial Details

NCT ID
NCT07746388
Phase
PHASE2
Sponsor
University of Maryland, Baltimore
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cemiplimab
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Age 18 years or older at time of study entry
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1
  • Participants with histologically confirmed stage II-IIIB(N2) NSCLC (per the 9th International Association for the Study of Lung Cancer) with diseas…
  • Subject cases must be reviewed in a multidisciplinary thoracic tumor board setting prior to enrollment to allow for adequate discussion regarding t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →